• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Kenvue Inc.

    6/2/25 4:27:41 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    SD 1 formsd-conflictsmineraldis.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    SPECIALIZED DISCLOSURE REPORT
    Kenvue Inc.
     (Exact name of the registrant as specified in its charter)

    Delaware001-4169788-1032011
    (State or other jurisdiction
     of incorporation or organization)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    1 Kenvue Way
    Summit, New Jersey
    07901
    (Address of principal executive offices)(Zip Code)

    Meredith Stevens, (908) 874-1200
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:
    ☑    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ☐    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _________.
        




    Section 1 – Conflict Minerals Disclosure 
    Item 1.01 Conflict Minerals Disclosure and Report 
    Conflict Minerals Disclosure 
    Kenvue, Inc. (together with its consolidated subsidiaries, “Kenvue”, “Company”, “we”, or “our”) hereby files this Form SD pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”) for the reporting period from January 1, 2024 to December 31, 2024 (the “Reporting Period”). Please refer to Rule 13p-1, Form SD and the 1934 Act Release No. 34-67716 for definitions to the terms used in this Report, unless otherwise defined herein. A copy of this Form SD is also posted to the Company’s website at: https://investors.kenvue.com.
     The Rule generally provides that a company must file a specialized disclosure report if it manufactures or contracts to manufacture products for which one or more of the following minerals are necessary to the functionality or production of the company’s products: cassiterite; columbite-tantalite (coltan); and wolframite; their derivatives tantalum, tin, and tungsten; and gold (collectively, “3TGs”). These are considered “conflict minerals” under the Rule regardless of their geographic origin and whether or not they fund armed conflict in the Democratic Republic of the Congo or its neighboring countries (the “covered countries”).
    Kenvue is a global leader at the intersection of healthcare and consumer goods and the world’s largest pure-play consumer health company by revenue with $15.5 billion in Net sales in the fiscal year 2024. Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products. Our in-house manufacturing footprint delivered over 60% of our sales volume in 2024, with the remaining sales volume being supplied by an extensive global network of external manufacturing facilities (EMs) operated by third-party manufacturers. 
    Pursuant to the Rule, we conducted in good faith a technical review of Kenvue’s products and surveyed our suppliers and EMs for the calendar year 2024 to determine whether 3TGs were present in our products. Based on this survey, we identified three (3) EMs (the “Covered EMs”) that supplied materials or products containing 3TGs to Kenvue, where such materials or products were as applicable included in products manufactured by Kenvue or contracted to be manufactured for Kenvue and 3TGs were necessary to the functionality or production of such materials or products. These products fell into the category of one electronic device, an RFID smart label for one product, and one formulated product that contains gold.
    Reasonable Country of Origin Inquiry
    For those materials or products that contain 3TGs, we conducted in good faith a reasonable country of origin inquiry to determine whether any 3TG necessary to the functionality or production of these materials or products (i) originated in the covered countries or (ii) was not from recycled or scrap sources. For any materials or products containing 3TGs, Kenvue conducted direct outreach to the Covered EMs to gather information regarding the presence and sourcing of 3TG in its products manufactured during the Reporting Period.
    Each of the 3 Covered EMs provided a completed Conflict Minerals Reporting Template published by the Responsible Minerals Initiative (“CMRT”). In their completed CMRTs, all of the Covered EMs confirmed that the 3TGs were not sourced from the covered countries for the materials or products supplied to Kenvue.
    Based on the reasonable country of origin inquiry described above, Kenvue has no reason to believe that any of the 3TGs contained in our products manufactured during the Reporting Period, that are within the scope of the Rule, originated in the covered countries or were not from recycled or scrap sources.
    Item 1.02 Exhibit 
    Not applicable.
    Section 3 – Exhibits 
    Item 3.01 Exhibits 
    Not applicable.



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    KENVUE INC.
    Date: June 2, 2025By:/s/ Meredith Stevens
      
    Name:
    Title:
    Meredith Stevens
    Chief Operations Officer


    Get the next $KVUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    5/28/2024$21.00Neutral
    Citigroup
    4/11/2024$18.00Underperform
    Bernstein
    More analyst ratings

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Redburn Atlantic initiated coverage on Kenvue with a new price target

    Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

    4/10/25 12:41:58 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Evercore ISI initiated coverage on Kenvue with a new price target

    Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

    3/24/25 8:39:49 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

    1/6/25 8:13:28 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

    8/14/25 1:07:20 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 10-Q filed by Kenvue Inc.

    10-Q - Kenvue Inc. (0001944048) (Filer)

    8/7/25 4:05:41 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    8/7/25 6:47:11 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue Reports Second Quarter 2025 Results

    Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne

    8/7/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Increases Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex

    7/30/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

    Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's

    7/25/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Group President APAC Dasgupta Anindya

    4 - Kenvue Inc. (0001944048) (Issuer)

    8/27/25 7:14:16 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 3 filed by new insider Dasgupta Anindya

    3 - Kenvue Inc. (0001944048) (Issuer)

    8/27/25 7:11:46 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 3 filed by new insider Wondrasch Michael

    3 - Kenvue Inc. (0001944048) (Issuer)

    8/27/25 4:50:57 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue Reports Second Quarter 2025 Results

    Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne

    8/7/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Increases Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex

    7/30/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

    Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's

    7/25/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary